Quanterix Narrows 2026 Revenue Outlook After Sequential Gain

The Tip Desk · November 9, 2026 · 3 min read

Third-quarter revenue was $35.0 million, up 6.3% from the second quarter, reversing a drop from $36.4 million in the first quarter.

Quanterix Corporation (QTRX), a global leader in precision biomarker science, reported third-quarter revenue of $35.0 million, a 6.3% sequential increase that reversed the prior quarter’s drop from $36.4 million in the first quarter to $32.9 million in the second.

President and Chief Executive Everett Cunningham said the company delivered higher-than-expected topline growth despite continued market softness and that the first step in restoring growth reflected sequential improvement across all businesses. He said actions initiated last quarter to improve commercial performance, including reorganizing teams and adding experienced leadership, should accelerate execution in the fourth quarter and beyond.

Product revenue was $25.2 million and service and other revenue $9.4 million in the three months ended September 30, 2026. Collaboration and license revenue was $0.4 million.

GAAP gross margin was 38.6%, down 90 basis points versus the prior year. Adjusted gross margin (non-GAAP) was 47.4%.

Net loss was $21.6 million, or $0.46 a share, an improvement of 35.6% compared with the year-earlier quarter. Adjusted EBITDA (non-GAAP) loss was $12.2 million.

Selling, general and administrative expense was $28.5 million in the three months ended September 30, 2026, versus $38.0 million a year earlier. Impairment and restructuring costs were $0.2 million, versus $7.2 million a year earlier. Research and development expense was $7.4 million.

Cash, cash equivalents, marketable securities, and restricted cash ended the quarter at $80.7 million, down from $96.9 million at the end of the second quarter.

Quanterix is narrowing its expectations for 2026 total revenues to $142 million to $146 million. The company continues to expect adjusted gross margins (non-GAAP) in a range of 48% to 50%. It now expects to end 2026 with a cash balance of approximately $70 million and no debt. In the second-quarter release, the company had revised its 2026 outlook and extended the date for attaining cash-flow break-even.

The company said it finished building its senior management team for planned growth, especially in diagnostics. Jim Gute was named Chief Commercial Officer in mid-August, and Dr. Yuri Fesko was named the company’s first Chief Medical Officer in September.

Beginning November 1, 2026, traditional Medicaid members and state employees in Florida can receive coverage for qualifying blood-based biomarker tests, including Quanterix’s LucentAD Complete, when medical necessity criteria are met. The company added two commercial partnerships with regional full-service clinical reference labs, Sherman Abrams Lab in New York and TruPath in Mississippi, which it said are underway and generating opportunities for diagnostics revenue.

New regulatory approvals in China advanced access to neurology biomarker testing on Quanterix’s HD-X and SR-X instruments and kits for four biomarkers, with Innovita Biological Technology Co. broadening access to blood biomarker testing as part of a strategy to bring SIMOA-powered diagnostics to large markets through regional partners.

The PhenoCode 2.0 Molecular Barcoding Kit is now in full commercial release. A TIME panel and a high-plex ADC panel are both shipping in early 2027. The Accelerator Lab is now accepting requests for custom ADC panel development.

Cunningham said the company has established a foundation in diagnostics through strategic investments and partnerships, enabling a focus on Alzheimer’s disease testing with a single-site five-biomarker blood test.